183 related articles for article (PubMed ID: 17537223)
1. Botulinum toxin a in the overactive bladder: current status and future directions.
Mallina R; Sahai A; Khan MS; Dasgupta P
BJU Int; 2007 Jun; 99(6):1549-50. PubMed ID: 17537223
[No Abstract] [Full Text] [Related]
2. Botulinum toxin A in the overactive bladder: current status and future directions.
Dmochowski R; Sand PK
BJU Int; 2007 Feb; 99(2):247-62. PubMed ID: 17313422
[No Abstract] [Full Text] [Related]
3. Botulinum toxin--new mechanisms, new therapeutic directions?
Chapple C; Patel A
Eur Urol; 2006 Apr; 49(4):606-8. PubMed ID: 16457945
[No Abstract] [Full Text] [Related]
4. Editorial comment on: neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
Wyndaele JJ
Eur Urol; 2008 May; 53(5):1019-20. PubMed ID: 17950988
[No Abstract] [Full Text] [Related]
5. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
6. Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity.
Sangster P; Kalsi V
BJU Int; 2008 Jul; 102 Suppl 1():17-9. PubMed ID: 18665974
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA; Srougi M; Coelho RF; de Campos Freire G
Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
[TBL] [Abstract][Full Text] [Related]
8. [Guidelines for treatment of urinary incontinence in women due to refractory idiopathic vesical hyperactivity with botulinum toxin A].
Peyrat L; Ragni E;
Prog Urol; 2010 Feb; 20 Suppl 2():S170-3. PubMed ID: 20403570
[TBL] [Abstract][Full Text] [Related]
9. Changing treatments for overactive bladder.
Waine E; Stott M
Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
[TBL] [Abstract][Full Text] [Related]
10. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population.
White WM; Pickens RB; Doggweiler R; Klein FA
J Urol; 2008 Dec; 180(6):2522-6. PubMed ID: 18930481
[TBL] [Abstract][Full Text] [Related]
11. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
[TBL] [Abstract][Full Text] [Related]
12. The current standing of intramural injection of botulinum neurotoxin in managing the overactive bladder.
Drake MJ
BJU Int; 2008 Jul; 102 Suppl 1():1. PubMed ID: 18665970
[No Abstract] [Full Text] [Related]
13. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
Lemack GE
Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
[No Abstract] [Full Text] [Related]
14. The use of botulinum toxin type A in urological procedures.
Lajiness MJ
Urol Nurs; 2009; 29(6):445-50. PubMed ID: 20088238
[TBL] [Abstract][Full Text] [Related]
15. Editorial comment on: Intraprostatic and bladder-neck botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
Michel M
Eur Urol; 2008 Mar; 53(3):626-7. PubMed ID: 17950523
[No Abstract] [Full Text] [Related]
16. Editorial comment on: Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
Pickard R
Eur Urol; 2008 Mar; 53(3):626. PubMed ID: 17950524
[No Abstract] [Full Text] [Related]
17. Re: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Cartwright R; Cardozo L
J Urol; 2007 Feb; 177(2):796-7; author reply 797. PubMed ID: 17222687
[No Abstract] [Full Text] [Related]
18. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.
Schmid DM; Roy S; Sulser T; Scheiner D
BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972
[TBL] [Abstract][Full Text] [Related]
19. Re: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2008 Feb; 101(4):515-6; author reply 516-7. PubMed ID: 18234066
[No Abstract] [Full Text] [Related]
20. Refractory neurogenic detrusor overactivity.
Cruz F; Silva C
Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
